- Home
- ATRC vs ETNB Comparison
ATRC vs ETNB Comparison
Compare ATRC & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRC
- ETNB
- Stock Information
- Founded
- ATRC 2000
- ETNB 2018
- Country
- ATRC United States
- ETNB United States
- Employees
- ATRC N/A
- ETNB N/A
- Industry
- ATRC Medical/Dental Instruments
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- ATRC Health Care
- ETNB Health Care
- Exchange
- ATRC Nasdaq
- ETNB Nasdaq
- Market Cap
- ATRC 1.7B
- ETNB 1.5B
- IPO Year
- ATRC 2005
- ETNB 2019
- Fundamental
- Price
- ATRC $35.83
- ETNB $7.91
- Analyst Decision
- ATRC Strong Buy
- ETNB Strong Buy
- Analyst Count
- ATRC 10
- ETNB 10
- Target Price
- ATRC $49.60
- ETNB $27.22
- AVG Volume (30 Days)
- ATRC 416.8K
- ETNB 1.4M
- Earning Date
- ATRC 10-28-2025
- ETNB 11-06-2025
- Dividend Yield
- ATRC N/A
- ETNB N/A
- EPS Growth
- ATRC N/A
- ETNB N/A
- EPS
- ATRC N/A
- ETNB N/A
- Revenue
- ATRC $499,946,000.00
- ETNB N/A
- Revenue This Year
- ATRC $16.32
- ETNB N/A
- Revenue Next Year
- ATRC $12.37
- ETNB N/A
- P/E Ratio
- ATRC N/A
- ETNB N/A
- Revenue Growth
- ATRC 16.28
- ETNB N/A
- 52 Week Low
- ATRC $25.57
- ETNB $4.16
- 52 Week High
- ATRC $43.11
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- ATRC 50.53
- ETNB 48.70
- Support Level
- ATRC $34.57
- ETNB N/A
- Resistance Level
- ATRC $38.08
- ETNB $9.47
- Average True Range (ATR)
- ATRC 1.46
- ETNB 0.41
- MACD
- ATRC -0.24
- ETNB -0.39
- Stochastic Oscillator
- ATRC 37.06
- ETNB 82.12
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).